Inclusion Criteria:

- Patients with advanced ovarian carcinoma, who have failed one prior platinum and
taxane containing regimen

- Only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes
administered concomitantly

- At least one measurable lesion according to RECIST

- ECOG performance status 0 or 1

- at least 18 years old

- Adequate haematological function

- Adequate renal and hepatic functions

- Normal coagulation parameters

Exclusion Criteria:

- Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy
and subsequently progressed or relapsed after a treatment-free interval of > 12
months

- Pregnant or lactating patients

- Prior treatment with camptothecins

- Presence or history of CNS metastasis or carcinomatous leptomeningitis;

- Current active infection per investigator assessment;

- Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or
ulcerative colitis;

- Current history of chronic diarrhea >= grade 1 (CTCAE version 3);

- Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of
cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st
study treatment are allowed;

- Other uncontrolled, serious illness or medical condition, as determined by the
investigator;

- Concomitant (or within 4 weeks before inclusion) administration of any other
experimental drug under investigation;

- Concurrent treatment with any other anti-cancer therapy;

- Known HIV positivity or AIDS-related illness;

- Patients who cannot be regularly followed up for psychological, social, familial or
geographic reasons.